<DOC>
	<DOC>NCT01475461</DOC>
	<brief_summary>B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes</brief_summary>
	<brief_title>Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>patients with type 2 diabetes, on metformin, age between 1855 yrs, male or female patients with type 1 diabetes, medically unstable, unacceptable clinical laboratory test results at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>PF-04937319</keyword>
</DOC>